Volume 38, Issue 1, Pages (January 2013)

Slides:



Advertisements
Similar presentations
Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis  Dariush Haghmorad, Mohammad Bagher.
Advertisements

Volume 33, Issue 2, Pages (August 2010)
Volume 34, Issue 3, Pages (March 2011)
Volume 33, Issue 3, Pages (September 2010)
Th9 Cells Drive Host Immunity against Gastrointestinal Worm Infection
Volume 26, Issue 3, Pages (March 2007)
Volume 31, Issue 2, Pages (August 2009)
Sequential Polarization and Imprinting of Type 1 T Helper Lymphocytes by Interferon-γ and Interleukin-12  Edda G. Schulz, Luca Mariani, Andreas Radbruch,
Pascal Chappert, Nicolas Bouladoux, Shruti Naik, Ronald H. Schwartz 
Volume 32, Issue 3, Pages (March 2010)
Volume 43, Issue 2, Pages (August 2015)
Volume 30, Issue 4, Pages (April 2009)
Volume 32, Issue 5, Pages (May 2010)
Volume 33, Issue 2, Pages (August 2010)
Volume 31, Issue 2, Pages (August 2009)
Volume 33, Issue 3, Pages (September 2010)
Volume 44, Issue 6, Pages (June 2016)
Volume 34, Issue 1, Pages (January 2011)
Volume 29, Issue 1, Pages (July 2008)
Volume 33, Issue 5, Pages (November 2010)
T Cell-Produced Transforming Growth Factor-β1 Controls T Cell Tolerance and Regulates Th1- and Th17-Cell Differentiation  Ming O. Li, Yisong Y. Wan, Richard.
Volume 27, Issue 1, Pages (July 2007)
Volume 29, Issue 6, Pages (December 2008)
B Cell Receptor and CD40 Signaling Are Rewired for Synergistic Induction of the c-Myc Transcription Factor in Germinal Center B Cells  Wei Luo, Florian.
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Volume 36, Issue 6, Pages (June 2012)
Volume 33, Issue 4, Pages (October 2010)
Volume 22, Issue 2, Pages (February 2005)
Volume 32, Issue 5, Pages (May 2010)
Volume 39, Issue 5, Pages (November 2013)
Volume 32, Issue 1, Pages (January 2010)
Volume 36, Issue 1, Pages (January 2012)
Volume 40, Issue 3, Pages (March 2014)
Volume 32, Issue 1, Pages (January 2010)
Volume 29, Issue 1, Pages (July 2008)
Opposing Effects of TGF-β and IL-15 Cytokines Control the Number of Short-Lived Effector CD8+ T Cells  Shomyseh Sanjabi, Munir M. Mosaheb, Richard A.
Volume 36, Issue 4, Pages (April 2012)
CD4+ Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the Gut
Volume 43, Issue 6, Pages (December 2015)
Volume 35, Issue 2, Pages (August 2011)
Volume 44, Issue 1, Pages (January 2016)
Volume 31, Issue 4, Pages (October 2009)
Volume 31, Issue 6, Pages (December 2009)
E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity  Jee H. Lee, Chris Elly,
Volume 19, Issue 11, Pages (June 2017)
Volume 126, Issue 6, Pages (September 2006)
Karima R.R. Siddiqui, Sophie Laffont, Fiona Powrie  Immunity 
Volume 32, Issue 5, Pages (May 2010)
Volume 34, Issue 3, Pages (March 2011)
Volume 41, Issue 2, Pages (August 2014)
Volume 30, Issue 4, Pages (April 2009)
Volume 28, Issue 1, Pages (January 2008)
Volume 28, Issue 5, Pages (May 2008)
Volume 33, Issue 1, Pages (July 2010)
Volume 40, Issue 2, Pages (February 2014)
Volume 35, Issue 4, Pages (October 2011)
Volume 32, Issue 1, Pages (January 2010)
Volume 22, Issue 8, Pages (February 2018)
Volume 43, Issue 4, Pages (October 2015)
Volume 31, Issue 5, Pages (November 2009)
Volume 31, Issue 6, Pages (December 2009)
Volume 35, Issue 1, Pages (July 2011)
PU.1 Expression Delineates Heterogeneity in Primary Th2 Cells
Volume 39, Issue 5, Pages (November 2013)
Volume 29, Issue 5, Pages (November 2008)
Volume 32, Issue 5, Pages (May 2010)
Volume 37, Issue 4, Pages (October 2012)
Volume 37, Issue 2, Pages (August 2012)
Repulsive Guidance Molecule-a Is Involved in Th17-Cell-Induced Neurodegeneration in Autoimmune Encephalomyelitis  Shogo Tanabe, Toshihide Yamashita  Cell.
Volume 39, Issue 2, Pages (August 2013)
Presentation transcript:

Volume 38, Issue 1, Pages 53-65 (January 2013) The CD27 and CD70 Costimulatory Pathway Inhibits Effector Function of T Helper 17 Cells and Attenuates Associated Autoimmunity  Jonathan M. Coquet, Sabine Middendorp, Gerda van der Horst, Jop Kind, Elise A.M. Veraar, Yanling Xiao, Heinz Jacobs, Jannie Borst  Immunity  Volume 38, Issue 1, Pages 53-65 (January 2013) DOI: 10.1016/j.immuni.2012.09.009 Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 1 EAE Is Exacerbated in CD27- and CD70-Deficient Mice and Ameliorated in Cd70tg Mice (A–C) EAE was induced in WT (n = 17), Cd27−/− (n = 16), and Cd70Cre/Cre (n = 7) mice and mice were monitored daily for clinical signs of EAE over a period of 20 days. (A) Disease development as diagnosed by defined scores. (B) Overall survival. Mice with a disease score of 4 or more were sacrificed and a survival curve was generated. (A and B) p < 0.05 for Cd27−/− (indicated by #) and Cd70Cre/Cre (indicated by §) mice as compared to WT. (C) Cytokine production by CD4+ T cells in the spleen. Splenocytes were isolated at day 6, restimulated with MOG35-55 peptide, and analyzed for IL-17 and IFN-γ production by intracellular staining. Contour plots depict IL-17 and CD44 expression in gated CD4+ T cells. Numbers represent percentage of cells in the indicated gates. Graphs indicate the percentage of cytokine-expressing cells among gated CD4+ T cells. Data are from two experiments with WT (n = 9) and Cd27−/− (n = 10) mice, ∗p < 0.05. (D and E) EAE was induced in control Cd27+/− (n = 13) and Cd70tg;Cd27+/− (n = 10) mice and mice were monitored daily for clinical signs of EAE over a period of 20 days. (D) Disease development in both groups, ∗p < 0.05. (E) Frequency of disease severity. The percentage of mice with a disease score greater than 1 was plotted, ∗∗∗p < 0.001. See also Figure S2 and Table S1. Statistical significance was determined by Mann-Whitney U rank test (A, C, and D) and Log rank test (B, E). Immunity 2013 38, 53-65DOI: (10.1016/j.immuni.2012.09.009) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 2 Reduced Th17 Cell Generation in Cd70tg Mice with EAE (A) Cytokine production by CD4+ T cells in the CNS at day 20 after EAE induction. CNS-infiltrating cells were isolated, stimulated with PMA and ionomycin, and analyzed for IL-17 and IFN-γ production by intracellular staining. Contour plots depict IL-17- and IFN-γ-producing cells among gated CD4+ T cells of control Cd27+/− mice and Cd70tg;Cd27+/− mice with progressive (score > 1) and nonprogressive (score < 1) disease. Shown are mice with disease scores of 2 (left plot), 2 (middle), and 0.5 (right). Numbers depict the percentage of cells in each quadrant. Graphs indicate the percentage and absolute number (#) of cytokine-expressing cells among gated CD4+ T cells. Data are from two experiments with control (n = 7), Cd70tg score > 1 (n = 4), and Cd70tg score < 1 (n = 4) mice. (B) Cytokine production by CD4+ T cells in the spleen at day 20 was analyzed as described in Figure 1C. Graphs depict data from WT (n = 5) and Cd70tg (n = 3) mice. (C and D) Cytokine production by CD4+ T cells in the CNS (C) and spleen (D) at day 10. Analysis was done as outlined in (A) and (B). Data are from two experiments with control (n = 9) and Cd70tg (n = 6) mice. Statistical significance was determined by Mann-Whitney U test, ∗p < 0.05. Immunity 2013 38, 53-65DOI: (10.1016/j.immuni.2012.09.009) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 3 CD27 Signaling Reduces CCR6 but Not RORγt Expression in Th17 Cells of Mice with EAE EAE was induced in control Cd27+/− and Cd70tg;Cd27+/− mice and the spleen and CNS were harvested at day 10. CNS-infiltrating lymphocytes and splenocytes were restimulated in vitro as described in Figure 2 and analyzed by intracellular staining. (A and B) RORγt expression. Histograms depict RORγt expression on IL-17+IFN-γ− (bold black line, unfilled), IL-17+IFN-γ+ (light gray, filled), IL-17−IFN-γ+ (gray line, unfilled), and IL-17−IFN-γ− (dark gray, filled) cells in control and Cd70tg mice from the CNS (A) and the spleen (B). Bar graphs depict the percentage of RORγt+ cells among the gated population indicated. (C) CCR6 expression. Histograms depict the expression of CCR6 on control (gray line) or Cd70tg (black line) cytokine-producing cells as indicated. Bar graphs depict the percentage of CCR6+ cells among the gated population indicated. Results are comprised from one experiment with littermate control (n = 7) and Cd70tg (n = 3) mice. Statistical significance was determined by the Student’s t test, ∗p < 0.05. Immunity 2013 38, 53-65DOI: (10.1016/j.immuni.2012.09.009) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 4 CD27 Signaling Impairs Th17 Cell Differentiation In Vitro Naive CD4+ T cells (CD4+CD25−CD44lo) were purified from spleens of WT or Cd27−/− mice and cultured for 4 days with irradiated splenocytes under Th17 or Th1 cell differentiation conditions, in the presence or absence of 1 μg/ml agonistic recombinant CD70 (FcCD70). After culture, cells were stimulated with PMA and ionomycin and analyzed for IL-17 and IFN-γ by intracellular staining. (A) Contour plots depict IL-17- and IFN-γ-producing cells. Numbers indicate the percentage of cells in the quadrants. (B) Graphs of the percentage and number of IL-17+ cells per well. Data are pooled from three experiments with duplicate cultures (n = 6). (C and D) In separate experiments, cells were costimulated with FcCD70 and IL-2Rα mAb (PC-61 mAb, 10 μg/ml) was added to the cultures as indicated. Graphs depict the percentage (C) and number (D) of cells per well that produce IL-17. Data are pooled from two experiments with duplicate cultures (n = 4). Statistical significance was determined by Mann-Whitney U test, ∗p < 0.05, ∗∗p < 0.01. See also Figure S3. Immunity 2013 38, 53-65DOI: (10.1016/j.immuni.2012.09.009) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 5 CD27 Signaling Inhibits Transcription of Il17a, Il17f, and CCR6 Genes but Does Not Affect Lineage Commitment of Th17 Cells (A and D) CD4+ T cells were cultured under Th17 cell differentiation conditions in presence or absence of FcCD70. After 4 days, triplicate cell samples were analyzed by quantitative PCR for transcription of the indicated genes. Messenger RNA expression was normalized to 18S ribosomal RNA. Data are representative of two experiments. Statistical significance was determined with the Student’s t test, ∗p < 0.05, ∗∗p < 0.01. (B and C) Cells were cultured under Th17 cell differentiation conditions in the presence (dotted line) or absence (solid line) of FcCD70, or with CD3 mAb as a control (shaded histogram) and analyzed for STAT-3 phosphorylation (B) after 20 hr or for Foxp3 (C) expression after 4 days of culture. Histograms are representative of two (B) or four (C) experiments. See also Tables S2–S4. Immunity 2013 38, 53-65DOI: (10.1016/j.immuni.2012.09.009) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 6 CD27 Inhibits IL-17 and CCR6 Expression via JNK Signaling Th17 cell differentiation cultures were performed in the presence or absence of FcCD70. (A) At 24, 48, or 96 hr, phosho(p)-JNK expression was analyzed by flow cytometry. The histogram shows control (secondary antibody) staining of cells cultured without (dark gray, filled) or with (light gray, filled) FcCD70 and staining with a p-JNK-specific primary antibody and secondary antibody on cells cultured without (solid black line) or with (dotted line) FcCD70 at the 48 hr time point. Graph depicts the percentage of p-JNK+ cells. Data are pooled from three experiments (n = 5–7). (B) Cells were cultured in the presence of the JNK inhibitor D-JNKI1 (3 μM) or vehicle control (−). At day 4, IL-17 and CCR6 expression was analyzed by flow cytometry as shown in the dot plots, with percentage of cells indicated in the quadrants. Graphs depict the fold increase in IL-17- or CCR6-expressing cells because of D-JNKI1 addition. Data are pooled from four experiments (n = 6). (C) Cells cultured as in (B) were analyzed for IL-17 mRNA expression by quantitative PCR, with normalization to 18S ribosomal RNA. Results are pooled from two experiments with a total of five separate cultures. (D) Cultures were performed in the presence of p38 MAP kinase inhibitor SB203580 (1 μM) or vehicle control (−) and IL-17 and CCR6 expression was analyzed as indicated in (B). Data are pooled from two experiments (n = 3–4). Statistical significance was determined by Mann-Whitney U test, ∗p < 0.05, ∗∗p < 0.01. Immunity 2013 38, 53-65DOI: (10.1016/j.immuni.2012.09.009) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 7 CD27 Signaling Epigenetically Silences the Il17a Gene CD4+ T cells were cultured under Th17 cell differentiation conditions in the presence or absence of FcCD70 for 4 days. (A–C) Chromatin immunoprecipitations (ChIP) were performed from 5 × 106 cells per sample with antibodies specific for total H3, H3K4me3, H3K14Ac, H3K27me3, and H3K9me2. (A and B) Isolated DNA was used as a template for quantitative PCR with primers specific for the Il17a gene promoter (A) or the Ifng promoter (B). Signals from ChIP of modified histone H3 were standardized to signals obtained from ChIP of total H3 (recovery was between 3% and 10%). Values from cells cultured in the presence of FcCD70 were normalized to values in its absence to allow for interexperimental comparison. Results are from three experiments. (C) H3K27me3 ChIP fractions were additionally used for next-generation sequencing. The graph shows the distribution of the H3K27me3 signal (normalized read count) over the Il17a locus, as detected in cells cultured without (black) or with (gray) FcCD70. The gene region presented includes a 1 kb promoter region (black line), the transcriptional start site (TSS), the coding region (gray line), and 3′ untranslated region (UTR). (D) Genomic demethylation restores IL-17 production by CD27-stimulated cells. The demethylating agent 5-azacytidine was added for the last 16 hr of Th17 cell differentiation culture. Contour plots depict IL-17- and IFN-γ-producing cells. The graph depicts the fold increase in percentage of IL-17+ cells in the presence of 5-aza in cultures with or without FcCD70. Data are pooled from four experiments (n = 9–10). Statistical significance was determined by Mann-Whitney U test, ∗∗∗p < 0.001. Immunity 2013 38, 53-65DOI: (10.1016/j.immuni.2012.09.009) Copyright © 2013 Elsevier Inc. Terms and Conditions